Previous close | 5.09 |
Open | 5.08 |
Bid | 5.18 x 1000 |
Ask | 5.22 x 1000 |
Day's range | 5.07 - 5.30 |
52-week range | 4.71 - 12.43 |
Volume | |
Avg. volume | 2,098,308 |
Market cap | 743.699M |
Beta (5Y monthly) | 1.38 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ROCKVILLE, Md. & EDMONTON, Alberta, May 01, 2024--In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.
ROCKVILLE, Md. & EDMONTON, Alberta, April 30, 2024--The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
ROCKVILLE, Md. & EDMONTON, Alberta, April 16, 2024--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference